Being Patient Senior Reporter Phil Gutis spent the day with our patient advisor, Jeff Borghoff, who was the first recipient in Biogen’s latest trial…
Frustrated for decades with failure after failure in efforts to find effective medications to treat Alzheimer’s and other cognitive disorders, researchers are now increasingly…
Almost a year ago, the phones and social media feeds of about 4,000 people around the world began to explode. Biogen had unexpectedly—and quite…
The U.S. Food and Drug Administration (FDA) has approved a re-dosing study for patients formerly enrolled in Biogen’s phase three clinical trials of its…
Biogen has agreed to buy an experimental Alzheimer’s and Parkinson’s treatment from Pfizer, the company announced Monday. In the agreed deal, Biogen will pay…
Biogen announced this week that it was cancelling the dementia drug it was testing in a Phase 2 trial that aimed to fight tau…
Last week, Biogen announced that its Alzheimer’s drug aducanumab was effective in combating Alzheimer’s disease, and that it would be reviving a trial cancelled…
Follow us